Guided Therapeutics, Inc.
GTHP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $117 | $0 | $1 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | $0 | $38 | $25 | $3 |
| Gross Profit | $35 | $79 | -$25 | -$2 |
| % Margin | – | 67.5% | – | -200% |
| R&D Expenses | $136 | $133 | $74 | $139 |
| G&A Expenses | $362 | $658 | $267 | $323 |
| SG&A Expenses | $384 | $709 | $340 | $392 |
| Sales & Mktg Exp. | $22 | $51 | $73 | $69 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $520 | $842 | $414 | $532 |
| Operating Income | -$485 | -$763 | -$414 | -$533 |
| % Margin | – | -652.1% | – | -53,300% |
| Other Income/Exp. Net | -$257 | -$48 | -$13 | -$119 |
| Pre-Tax Income | -$742 | -$811 | -$427 | -$652 |
| Tax Expense | $43 | $0 | $0 | $0 |
| Net Income | -$785 | -$811 | -$427 | -$652 |
| % Margin | – | -693.2% | – | -65,200% |
| EPS | -0.01 | -0.011 | -0.007 | -0.012 |
| % Growth | 8.3% | -60.3% | 44.7% | – |
| EPS Diluted | -0.01 | -0.011 | -0.007 | -0.012 |
| Weighted Avg Shares Out | 81,689 | 78,838 | 68,291 | 57,339 |
| Weighted Avg Shares Out Dil | 81,689 | 78,838 | 68,291 | 57,339 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $129 | $157 | $147 | $134 |
| Depreciation & Amortization | $27 | $27 | $25 | $24 |
| EBITDA | -$586 | -$627 | -$255 | -$494 |
| % Margin | – | -535.9% | – | -49,400% |